Accepted Manuscript

How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?

T.W. Felton, W.W. Hope, J.A. Roberts

PII: S0732-8893(14)00167-9

DOI: doi: 10.1016/j.diagmicrobio.2014.04.007

Reference: DMB 13602

To appear in: Diagnostic Microbiology and Infectious Disease

Received date: 9 April 2013 Revised date: 14 April 2014 Accepted date: 22 April 2014



Please cite this article as: Felton TW, Hope WW, Roberts JA, How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?, *Diagnostic Microbiology and Infectious Disease* (2014), doi: 10.1016/j.diagmicrobio.2014.04.007

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

EPTED MANUS

How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done

about it?

Felton TW¹, Hope WW², Roberts JA³

¹The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational

Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation

Trust, Manchester, UK; ²Department of Molecular and Clinical Pharmacology, University of

Liverpool, Liverpool L69 3GE, UK; ³Burns Trauma and Critical Care Research Centre, The University of

Queensland, Brisbane and Royal Brisbane and Women's Hospital Brisbane, Queensland, Australia.

Dr Felton is a MRC Clinical Training Fellow supported by the North West England Medical Research

Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the

Medical Research Council (grant number G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca

and the Medical Evaluation Unit. Professor Hope is supported by a Clinician Scientist Fellowship

from the National Institute of Health Research. Dr Roberts is funded by a Career Development

Fellowship from the National Health and Medical Research Council of Australia (APP1048652).

Corresponding Author:

Timothy W Felton

Clinical Research Fellow

The University of Manchester

Manchester Academic Health Science Centre

NIHR Translational Research Facility in Respiratory Medicine

University Hospital of South Manchester NHS Foundation Trust

Manchester, UK

Mobile:+44 291 5811; Tel: +44 161 275 1682; Email: timothy.felton@manchester.ac.uk

1

Download English Version:

https://daneshyari.com/en/article/6115876

Download Persian Version:

https://daneshyari.com/article/6115876

<u>Daneshyari.com</u>